- Home
- RCEL vs SGHT Comparison
RCEL vs SGHT Comparison
Compare RCEL & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- SGHT
- Stock Information
- Founded
- RCEL 2020
- SGHT 2011
- Country
- RCEL United States
- SGHT United States
- Employees
- RCEL N/A
- SGHT N/A
- Industry
- RCEL Medical/Dental Instruments
- SGHT Medical Specialities
- Sector
- RCEL Health Care
- SGHT Health Care
- Exchange
- RCEL Nasdaq
- SGHT Nasdaq
- Market Cap
- RCEL 308.6M
- SGHT 304.4M
- IPO Year
- RCEL N/A
- SGHT 2021
- Fundamental
- Price
- RCEL $8.73
- SGHT $2.89
- Analyst Decision
- RCEL Buy
- SGHT Buy
- Analyst Count
- RCEL 5
- SGHT 7
- Target Price
- RCEL $18.00
- SGHT $5.10
- AVG Volume (30 Days)
- RCEL 251.2K
- SGHT 260.5K
- Earning Date
- RCEL 02-13-2025
- SGHT 03-06-2025
- Dividend Yield
- RCEL N/A
- SGHT N/A
- EPS Growth
- RCEL N/A
- SGHT N/A
- EPS
- RCEL N/A
- SGHT N/A
- Revenue
- RCEL $60,040,000.00
- SGHT $79,543,000.00
- Revenue This Year
- RCEL $36.71
- SGHT $2.13
- Revenue Next Year
- RCEL $54.48
- SGHT $7.99
- P/E Ratio
- RCEL N/A
- SGHT N/A
- Revenue Growth
- RCEL 32.24
- SGHT N/A
- 52 Week Low
- RCEL $7.51
- SGHT $2.68
- 52 Week High
- RCEL $18.93
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- RCEL 31.80
- SGHT 26.68
- Support Level
- RCEL $8.53
- SGHT $2.68
- Resistance Level
- RCEL $9.42
- SGHT $3.34
- Average True Range (ATR)
- RCEL 0.65
- SGHT 0.16
- MACD
- RCEL -0.39
- SGHT -0.03
- Stochastic Oscillator
- RCEL 3.89
- SGHT 20.38
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.